The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability

Stopped early · Phase 4

Conditions studied: Anemia, End Stage Renal Disease

In brief

Hypothesis: Routine clinical tests with feedback control based Epogen(Epo)/Venofer(Iron) protocol will improve Hemoglobin (Hgb) stability and increase the time that patients remain in target Objectives: 1. Decreased variability of Hgb 2. Increase the % of patients in target range c Increase in time that Hgb remains target range

Key facts

Study ID

NCT01975844

Run by

Michael Germain

People needed

48

Starts

2013-07-01

Last updated by the study team

2014-03-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years old or older
• Receiving hemodialysis in an out-patient dialysis unit

You may not qualify if…

• Not receiving EPOGEN as part of their standard medical care
• Patient refusal

Where it is running

• Chicopee Dialysis Center — Chicopee, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.